Abstract:OBJECTIVETo evaluate the efficacy and safety of standard term (12 months) or long term (> 12 months) dual antiplatelet therapy (DAPT) versus short term (< 6 months) DAPT after percutaneous coronary intervention (PCI) with drug-eluting stent (DES).DESIGNSystematic review and network meta-analysis.DATA SOURCESRelevant studies published between June 1983 and April 2018 from Medline, Embase, Cochrane Library for clinical trials, PubMed, Web of Science, ClinicalTrials.gov, and Clinicaltrialsregister.eu.REVIEW METHODSRandomised controlled trials comparing two of the three durations of DAPT (short term, standard term, and long term) after PCI with DES were included. The primary study outcomes were cardiac or non-cardiac death, all cause mortality, myocardial infarction, stent thrombosis, and all bleeding events.RESULTS17 studies (n=46 864) were included. Compared with short term DAPT, network meta-analysis showed that long term DAPT resulted in higher rates of major bleeding (odds ratio 1.78, 95% confidence interval 1.27 to 2.49) and non-cardiac death (1.63, 1.03 to 2.59); standard term DAPT was associated with higher rates of any bleeding (1.39, 1.01 to 1.92). No noticeable difference was observed in other primary endpoints. The sensitivity analysis revealed that the risks of non-cardiac death and bleeding were further increased for >= 18 months of DAPT compared with short term or standard term DAPT. In the subgroup analysis, long term DAPT led to higher all cause mortality than short term DAPT in patients implanted with newer-generation DES (1.99, 1.04 to 3.81); short term DAPT presented similar efficacy and safety to standard term DAPT with acute coronary syndrome (ACS) presentation and newer-generation DES placement. The heterogeneity of pooled trials was low, providing more confidence in the interpretation of results.CONCLUSIONSIn patients with all clinical presentations, compared with short term DAPT (clopidogrel), long term DAPT led to higher rates of major bleeding and non-cardiac death, and standard term DAPT was associated with an increased risk of any bleeding. For patients with ACS, short term DAPT presented similar efficacy and safety with standard term DAPT. For patients implanted with newer-generation DES, long term DAPT resulted in more all cause mortality than short term DAPT. Although the optimal duration of DAPT should take personal ischaemic and bleeding risks into account, this study suggested short term DAPT could be considered for most patients after PCI with DES, combining evidence from both direct and indirect comparisons.SYSTEMATIC REVIEW REGISTRATIONPROSPERO CRD42018099519.

The Importance of the Mean Platelet Aggregation Degree in Long-term Dual Antiplatelet Therapy Following Drug Eluting Stent Implantation.

The follow-up study of dual antiplatelet therapy (DAPT) duration and the prognosis of coronary heart diseases patients after drug-eluting stent (DES) implantation

Duration of Dual Antiplatelet Therapy after Implantation of the First-Generation and Second-Generation Drug-Eluting Stents

Novel insights on dual antiplatelet therapy duration following stenting for angiography-detected moderate-to-severe calcified coronary lesions

Comparative Efficacy and Safety of Duration of Dual Antiplatelet Therapy in Patients with CAD Undergoing Drug-eluting Stent Implantation: A Systematic Review and Network Meta-analysis.

Meta analysis of different durations of dual anti-platelet therapy after percutaneous coronary intervention with drug eluting stents in patients with coronary disease

Impact Of Six Versus 12 Months Of Dual Antiplatelet Therapy In Patients With Drug- Eluting Stent Implantation After Risk Stratification With The Residual Syntax Score: Results From A Secondary Analysis Of The I-Love- It 2 Trial

Duration Of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention With Drug-Eluting Stent: Systematic Review And Network Meta-Analysis

Clinical outcomes of dual antiplatelet therapy after implantation of drug-eluting stents in patients with different cardiovascular risk factors

Optimal duration of dual-antiplatelet therapy following drug-eluting stent implantation: a meta-analysis.

Short-term (1–3 months) versus standard (12 months) dual antiplatelet therapy following new-generation drug-eluting stent implantation: A meta-analysis of randomized controlled trials

Optimum of Dual Antiplatelet Duration and Followed Monotherapy in Diabetes Mellitus After Percutaneous Coronary Intervention With Drug-Eluting Stent Implantation: A Bayesian Network Meta-Analysis of 20536 Patients From 18 Randomized Trials

Meta Analysis of Dual Antiplatelet Therapy≤6 Months and Dual Antiplatelet Therapy≥12 Months in Patients After Drug-eluting Stent Implantation

Duration of dual antiplatelet therapy after percutaneous coronary intervention with implantation of second-generation drug-eluting stent: A meta-analysis of randomized controlled trials.

Efficacy and Safety of Dual Antiplatelet Therapy in Patients Undergoing Coronary Stent Implantation: A Systematic Review and Network Meta-Analysis

Prolonging Dual Antiplatelet Therapy Improves Long-term Prognosis in Diabetic Patients Undergoing Complex Percutaneous Coronary Intervention with Drug-eluting Stents

Short- versus long-term dual antiplatelet therapy after second-generation drug-eluting stent implantation in patients with diabetes mellitus: A meta-analysis of randomized controlled trials

High Platelet Reactivity Affects the Clinical Outcomes of Patients Undergoing Percutaneous Coronary Intervention

Abstract 11865: New Insights Into Optimal Duration of Dual Antiplatelet Therapy After Left Main Coronary Stenting: Findings From the Largest LM PCI Cohort

A retrospective study of the safety and efficacy of clopidogrel versus aspirin monotherapy one year after coronary stent implantation

Impact of extended dual antiplatelet therapy on clinical prognosis in acute coronary syndrome patients with intermediate or high ischemic risk defined by the GRACE score